Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Axsome Thera
(NQ:
AXSM
)
73.76
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Axsome Thera
< Previous
1
2
3
4
Next >
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
May 24, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
May 23, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Axsome Therapeutics, Inc. (AXSM) Investors
May 23, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTOR DEADLINE: Axsome Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AXSM
May 21, 2022
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
AXSM Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Axsome Therapeutics, Inc. (AXSM)
May 20, 2022
From
Robbins LLP
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Axsome Therapeutics, Inc. (AXSM) Investors
May 20, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Axsome Therapeutics, Inc. (AXSM) Investors
May 19, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Investors to Contact the Firm
May 19, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of Investors
May 18, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
Shareholder Alert: Did You Purchase Shares of Axsome Therapeutics, Inc. (AXSM)? Robbins LLP Alerts Investors of Class Action Against Axsome Therapeutics, Inc.
May 18, 2022
From
Robbins LLP
Via
Business Wire
AXSOME ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Axsome Therapeutics, Inc. and Encourages Investors to Contact the Firm
May 17, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of Investors
May 17, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of Investors
May 17, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm
May 17, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Axsome Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AXSM
May 16, 2022
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. With Losses of $500,000 to Contact the Firm
May 16, 2022
From
The Schall Law Firm
Via
Business Wire
EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
May 16, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Axsome Stockholders and Encourages Investors to Contact the Firm
April 26, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shareholder Notice: Investigation over Possible Wrongdoing
September 29, 2021
San Diego, CA -- (SBWIRE) -- 09/29/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Axsome Therapeutics, Inc.
Via
SBWire
Exposures
Product Safety
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shareholder Notice: Investigation over Possible Violations of Securities Laws
August 26, 2021
San Diego, CA -- (SBWIRE) -- 08/26/2021 -- Axsome Therapeutics, Inc is under investigation concerning possible securities laws violations in connection with certain financial statements.
Via
SBWire
Exposures
Product Safety
CORRECTING and REPLACING Scott+Scott Attorneys at Law LLP Announces Investigation into Axsome Therapeutics Inc. (AXSM)
August 11, 2021
From
Scott+Scott Attorneys at Law LLP
Via
Business Wire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Axsome Stockholders and Encourages Investors to Contact the Firm
August 10, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Scott+Scott Attorneys at Law LLP Announces Investigation into Axsome Therapeutics Inc. (AXSM)
August 10, 2021
From
Scott+Scott Attorneys at Law LLP
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors With Losses to Contact the Firm
August 09, 2021
From
The Schall Law Firm
Via
Business Wire
AXSM INVESTOR ALERT: Rosen Law Firm Encourages Axsome Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation – AXSM
August 09, 2021
From
The Rosen Law Firm, P.A.
Via
Business Wire
Parkinson’s Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027
May 05, 2021
Via
FinancialNewsMedia
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.